RxDoctor Payments Data

Pranav Diwan, MD

Interventional Cardiology · Thomasville, GANPI 1306152855

Payments from drug & device makers

$14,513in general payments, 2019–2025

Across 137 payments — averaging $105.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$12K
  • Novartis$411
  • Shockwave Medical, Inc$390
  • E.r. Squibb & Sons, L.L.C.$360
  • Abbott$172
  • Abiomed$136
  • plus $733 from 16 others

What the payments were for

  • Food & beverage$2,36316%
  • Other$12,15084%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,513 in reported general payments places this provider in the 60th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$179,477
Medicare patients
1,008
Services billed
2,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis40$895,128
EliquisApixaban682$533,215
EntrestoSacubitril/Valsartan328$268,861
FarxigaDapagliflozin Propanediol283$198,169
BrilintaTicagrelor275$168,173
JardianceEmpagliflozin150$105,060
XareltoRivaroxaban114$100,647
Repatha SureclickEvolocumab80$59,965
Ranolazine ErRanolazine293$18,465
NexlizetBempedoic Acid/Ezetimibe20$8,110
Praluent PenAlirocumab14$7,712
Metoprolol Succinate826$7,591
VascepaIcosapent Ethyl18$6,978
DapagliflozinDapagliflozin Propanediol14$6,729
ClopidogrelClopidogrel Bisulfate789$6,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$100$1,428,343722 claims
AstraZenecaFarxiga, Brilinta$70$366,342558 claims
NovartisEntresto$411$268,861328 claims
Boehringer IngelheimJardiance$17$105,060150 claims
Johnson & JohnsonXarelto$15$100,647114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →